Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study

Noller, Geoffrey E., Frampton, Chris M., Yazar-Klosinski, Berra · 2017 · The American Journal of Drug and Alcohol Abuse

AI-extracted · unverified · confirm at source

Single ibogaine treatment (mean 31.4 mg/kg) reduced ASI drug use score 81% at 12mo (p=0.002, n=8). BDI-II depression scores fell from 22.1 to 4.4 (p<0.001). 75% negative urine at 12mo. 1 fatality during treatment.

Dosing: 25–55 mg/kg oral (oral)

Sample size: 14

Contraindications: Pre-existing cardiovascular conditions, CYP2D6 poor metaboliser status, Hepatic impairment, Concomitant CYP2D6 inhibitors